US Patent 8,889,740: Scope, Claims, Expiration, and Amantadine Patent Landscape

US Patent 8,889,740 protects once-daily amantadine dosage forms that combine extended release with a defined human pharmacokinetic profile. The core limitation is not simply controlled release. The dosage form must reduce the rate of plasma-concentration change during hours 2 to 4, compared with an immediate-release amantadine product during hours 0 to 2.

The patent is most relevant to osmotic and other extended-release amantadine products, including products in the commercial space occupied by Osmolex ER. Its broadest claim covers a 50 mg to 500 mg dosage form containing amantadine or a pharmaceutically acceptable salt, with at least 50% of the drug in extended-release form. The patent does not require an osmotic device unless claim 2 is asserted.

What does US Patent 8,889,740 protect?

US 8,889,740 protects a dosage form defined by four principal elements:

Claim element	Scope
Active ingredient	Amantadine or a pharmaceutically acceptable salt
Total drug amount	50 mg to 500 mg
Release profile	At least 50% of drug in extended-release form
Pharmacokinetics	The 2-to-4-hour dC/dT is less than 30% of the comparator immediate-release dC/dT measured over 0 to 2 hours

Claim 1 is an apparatus or product claim directed to the dosage form itself. It is not limited to treatment of Parkinson's disease, dyskinesia, influenza, or any other indication.

The claim is drafted around a functional pharmacokinetic result. A product must satisfy the specified plasma-concentration relationship in a single-dose human pharmacokinetic study. A formulation that releases amantadine slowly but does not meet the dC/dT threshold may fall outside the literal scope of claim 1.

How broad is independent claim 1?

Claim 1 is broad in formulation terms but narrower in pharmacokinetic terms.

Active ingredient limitation

The claim covers:

Amantadine free base;
Amantadine hydrochloride;
Other pharmaceutically acceptable salts of amantadine.

The claim does not cover unrelated dopaminergic agents, NMDA antagonists, or combination products lacking amantadine. It also does not require a particular salt, particle size, coating material, osmotic membrane, polymer, or manufacturing process.

Dose limitation

The claimed dosage form must contain 50 mg to 500 mg of drug. The dependent claims create narrower ranges:

Claim 3: 100 mg to 500 mg;
Claim 4: 200 mg to 500 mg.

A product containing less than 50 mg or more than 500 mg would not literally satisfy claim 1, although a doctrine-of-equivalents argument could be attempted depending on the factual record and prosecution history.

The claim appears directed to the amount of amantadine drug substance in the dosage form, rather than necessarily the total mass of amantadine salt. Salt-form conversions can therefore become relevant in a product-by-product infringement analysis.

Extended-release limitation

At least 50% of the drug must be in extended-release form. Claims 5 and 6 narrow that requirement to:

At least 75% extended release; and
At least 90% extended release.

Claim 9 confirms that the dosage form may include both extended-release and immediate-release amantadine. The patent therefore reaches mixed-release products, provided the extended-release fraction and pharmacokinetic result satisfy the claim.

The claim does not require 100% extended release. This distinction is commercially important because a formulation can include an immediate-release loading fraction while remaining within the dependent claim structure.

What is the key pharmacokinetic limitation?

The principal limitation is the comparative dC/dT requirement.

The claimed dosage form must produce a mean change in plasma amantadine concentration over the period from two to four hours after administration that is less than 30% of the dC/dT generated by the same quantity of amantadine in an immediate-release dosage form over zero to two hours.

In simplified form:

[ \frac{(dC/dT){ER,2-4h}}{(dC/dT){IR,0-2h}} < 0.30 ]

This limitation has several consequences:

The comparison is against an immediate-release form.
The comparison uses the same quantity of drug.
The claimed measurement is based on a single-dose human pharmacokinetic study.
The relevant periods are fixed at two to four hours for the extended-release product and zero to two hours for the immediate-release comparator.
The result is based on a mean change in plasma concentration, not merely an in vitro dissolution profile.

The dC/dT requirement may make infringement technically demanding. A patent owner would generally need formulation data, clinical pharmacokinetic data, or a scientifically defensible bridge between the accused product and the claimed profile. Routine dissolution testing alone may not establish the limitation.

What do claims 2 through 9 add?

Claim	Added limitation	Commercial significance
2	Osmotic device using osmotic driving force	Targets osmotic pump and related osmotic-release systems
3	100 mg to 500 mg drug amount	Excludes the 50 mg to less-than-100 mg range
4	200 mg to 500 mg drug amount	Targets higher-dose products
5	At least 75% extended release	Narrows the release composition
6	At least 90% extended release	Covers formulations with little immediate-release drug
7	Tmax shifted by 2 to 16 hours versus immediate release	Adds a delayed-peak limitation
8	Extent of drug bioavailability maintained	Prevents reduced exposure from being used to achieve the release profile
9	Includes immediate-release drug	Expressly covers biphasic or loading-dose products

Claim 2 is the most important dependent claim for an osmotic product. It requires more than prolonged release. The device must use an osmotic driving force. A conventional hydrophilic matrix, coated multiparticulate, wax matrix, or diffusion-controlled tablet could satisfy claim 1 but not necessarily claim 2.

Claim 7 adds a Tmax limitation. It requires the extended-release form to shift the time of maximum plasma concentration by two to 16 hours relative to immediate-release amantadine. The claim does not specify a particular Tmax value; it specifies the magnitude of the shift.

Claim 8 addresses exposure. A formulation that slows release but materially reduces systemic exposure could fail the maintained-bioavailability limitation of claim 8 while still potentially satisfying claim 1.

What formulations are protected by US 8,889,740?

The patent can reach several formulation categories if they meet the claim 1 pharmacokinetic test.

Osmotic dosage forms

An osmotic tablet or capsule is the clearest target for claim 2. Relevant technical components may include:

A drug-containing compartment;
A semipermeable membrane;
An osmotic push layer;
An osmotic agent;
A delivery orifice;
Excipients controlling water ingress and drug expulsion.

The patent claim does not require any particular membrane polymer, orifice size, layer architecture, or osmotic excipient.

Mixed immediate-release and extended-release systems

Claim 9 can cover products with an immediate-release loading portion and a sustained-release portion. Examples include:

Bilayer tablets;
Capsules containing immediate-release and extended-release beads;
Tablets containing an immediate-release coating over an extended-release core;
Multiparticulate systems with different coating thicknesses.

Non-osmotic extended-release systems

Claim 1 is not limited to osmotic technology. It may reach:

Hydrophilic matrix tablets;
Hydrophobic matrix systems;
Reservoir-coated particles;
Ion-exchange resin systems;
Polymer-coated beads;
Combination immediate-release/extended-release dosage forms.

The decisive issue remains the claimed human pharmacokinetic profile.

When does US Patent 8,889,740 lose exclusivity?

US 8,889,740 issued on November 18, 2014. Public patent records identify a 2011-era nonprovisional filing and an estimated ordinary patent-term endpoint in approximately 2031, subject to the actual patent-term-adjustment calculation, terminal disclaimers, and any applicable statutory adjustment.[1]

The relevant dates are:

Event	Date
Patent issued	November 18, 2014
Ordinary patent term	Generally 20 years from the applicable nonprovisional filing date
Estimated nominal expiry	Approximately 2031
FDA exclusivity	Separate from patent term and product-specific
Pediatric extension	No extension should be assumed without an applicable FDA determination

Patent expiration does not automatically eliminate all regulatory barriers. An amantadine generic may face separate listed patents, FDA exclusivity, labeling restrictions, or litigation-related delays.

The patent’s effective commercial blocking date therefore depends on the entire Orange Book listing for the relevant reference-listed drug, not US 8,889,740 alone.

What is the Orange Book status of US 8,889,740?

US 8,889,740 is commercially associated with extended-release amantadine products and is relevant to the Orange Book analysis for Osmolex ER. The FDA Orange Book must be reviewed by product and strength because listing status, patent use codes, and delisting actions can change over time.[2]

Osmolex ER is an extended-release amantadine hydrochloride product approved by FDA under NDA 209530. Its product design is relevant to the patent because it uses a once-daily extended-release approach and includes strengths within the claim's numerical dose range.[3]

The Orange Book analysis should separate:

Patent listing status;
Listed use code, if any;
Patent expiration date reported by FDA;
Whether the patent is listed against all strengths;
Whether the patent covers the approved labeling or only a formulation;
Whether the NDA holder has submitted a delisting request.

A patent covering the dosage form can create a Paragraph IV barrier even if the generic applicant does not seek approval for a patented method of treatment.

Which products compete with the claimed technology?

Osmolex ER

Osmolex ER is the closest commercial product to the claim set because the patent expressly includes an osmotic device in claim 2 and covers once-daily extended-release amantadine in the 50 mg to 500 mg range.

Osmolex ER was approved in 2018 for treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults. The marketed strengths are within the numerical boundaries of the patent claims.[3]

Gocovri

Gocovri is an extended-release amantadine product developed by Adamas Pharmaceuticals and marketed by Neurocrine Biosciences. FDA approved Gocovri in 2017 for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic therapy.[4]

Gocovri is a competing extended-release amantadine product, but competition does not establish that it falls within US 8,889,740. Its formulation architecture, release profile, dose, and patent portfolio must be analyzed separately. Its principal commercial indication and product design differ from the osmotic-product profile most directly implicated by claim 2.

Immediate-release amantadine

Generic amantadine hydrochloride capsules, tablets, and oral solutions are important comparators but are generally outside the patent's extended-release requirement. An immediate-release product could still be relevant as the comparator used in the patent's dC/dT and Tmax limitations.

Product category	Likely relationship to US 8,889,740
Immediate-release amantadine	Generally outside claim 1 because at least 50% must be extended release
Osmotic once-daily amantadine	Highest potential relevance, particularly claim 2
Matrix extended-release amantadine	Potential claim 1 exposure if PK limitations are met
Multiparticulate extended-release amantadine	Potential claim 1 exposure; claim 2 depends on osmotic mechanism
Gocovri-type extended-release product	Requires separate formulation and PK comparison
Amantadine product below 50 mg	Outside the literal dose range
Product above 500 mg	Outside the literal dose range

How strong is the patent estate?

US 8,889,740 has meaningful claim breadth but a relatively demanding proof structure.

Strengths

Covers the active ingredient at the genus level.
Covers a broad 50 mg to 500 mg dose range.
Does not require a specific excipient.
Reaches multiple extended-release technologies.
Includes mixed immediate-release and extended-release products.
Adds a specific osmotic-device claim.
Uses clinically relevant PK limitations that can distinguish routine sustained-release products.

Vulnerabilities

The claim depends on human PK testing.
The dC/dT comparison requires a defined immediate-release comparator.
The claim uses multiple time windows that may create measurement disputes.
“Same quantity of the drug” may require careful salt and dose normalization.
The phrase “at least 50% ... in an extended release form” may raise questions about how release fractions are measured.
Claim 8's maintained-bioavailability requirement may be difficult to apply without a defined baseline.
Prior-art sustained-release amantadine formulations could be relevant to validity, particularly if they disclosed comparable dose ranges and PK behavior.

The patent is strongest against a once-daily amantadine product whose human PK profile was intentionally designed to reduce early concentration changes and delay Tmax. It is weaker against a product that uses a different release architecture and does not meet the specified PK thresholds.

What generic entry risks exist?

A generic applicant for an extended-release amantadine product could face three primary pathways:

Paragraph III certification

The applicant accepts the listed patent and delays approval until expiration. This avoids patent litigation but postpones market entry.

Paragraph IV certification

The applicant asserts that the patent is invalid, unenforceable, or not infringed. For US 8,889,740, likely noninfringement arguments would focus on:

Less than 50% extended-release drug;
Dose outside the 50 mg to 500 mg range;
Failure to meet the dC/dT threshold;
Failure to shift Tmax by the required amount;
Non-osmotic design under claim 2;
Failure to maintain bioavailability under claim 8.

Validity arguments could target written description, enablement, indefiniteness of the PK limitations, anticipation, or obviousness based on prior extended-release amantadine systems and known once-daily formulation principles.

Section viii statement

If the listed patent is associated only with a method of use, a generic applicant may seek approval with a carved-out label. That route is less useful when the patent claims the dosage form itself, as claim 1 does.

Is there biosimilar risk?

There is no biosimilar pathway for amantadine. Amantadine is a small-molecule drug regulated through the abbreviated new drug application pathway rather than the Biologics Price Competition and Innovation Act pathway.

The relevant competitive threats are:

Generic immediate-release amantadine;
Generic extended-release amantadine;
Authorized or licensed extended-release products;
Reformulated products with different release mechanisms;
Products using labeling that avoids patented indications.

What patent litigation and Paragraph IV challenges affect the product?

The principal litigation risk would arise from an ANDA filing directed to an extended-release amantadine product listed against the patent. A final assessment requires the FDA Orange Book, FDA Paragraph IV notice information, and PACER or district-court records.

No conclusion that a particular generic company has successfully invalidated or cleared US 8,889,740 should be drawn solely from the patent document. Patent issuance, Orange Book listing, litigation, settlement, and generic approval are separate events.

A settlement could allow an authorized generic, license, or agreed entry date without producing a published invalidity judgment. Such an agreement would need to be evaluated under the FTC's pharmaceutical patent-settlement reporting framework and the relevant court docket.[5]

What licensing and ownership issues matter?

Commercial ownership is separate from inventorship and original patent assignment. The relevant diligence points are:

Current recorded assignee at the USPTO;
NDA holder for the product associated with the patent;
Any exclusive license covering the patent;
Change-of-control transactions;
Security interests or collateral assignments;
Whether a license extends to ANDA settlements or authorized-generic rights.

For the broader extended-release amantadine market, Adamas Pharmaceuticals became part of Supernus Pharmaceuticals, while Neurocrine Biosciences markets Gocovri under its commercial arrangements with Adamas. Those transactions relate primarily to the Gocovri business and should not be treated as proof of ownership or licensing rights under US 8,889,740.[6]

How does US 8,889,740 compare with competing patent strategies?

Patent strategy	US 8,889,740	Typical alternative strategy
Primary protection	Dosage form plus PK result	Composition, manufacturing, or method of treatment
Active ingredient	Amantadine and salts	Specific salt or formulation
Dose	50 mg to 500 mg	Narrow commercial strength
Technology	Any ER system in claim 1; osmotic system in claim 2	Specific bead, matrix, or capsule architecture
Clinical limitation	dC/dT and, in claim 7, Tmax shift	Indication-specific efficacy or dosing
Generic vulnerability	PK testing and claim construction	Design-around of formulation structure
Geographic coverage	United States only	Separate national patents required elsewhere

The patent's principal differentiation is its use of pharmacokinetic performance as a claim boundary. This approach can cover multiple technical implementations, but it also creates litigation exposure around study design, statistical treatment, sampling intervals, and comparator selection.

Key Takeaways

US 8,889,740 covers once-daily amantadine dosage forms containing 50 mg to 500 mg, with at least half of the drug in extended-release form.
The central limitation is a human PK result: the 2-to-4-hour dC/dT must be less than 30% of the corresponding immediate-release comparator value over zero to two hours.
Claim 1 is not limited to osmotic technology. Claim 2 adds the osmotic-device limitation.
Claims 5, 6, and 9 make the patent relevant to formulations with predominantly extended-release drug and to products containing both immediate-release and extended-release amantadine.
Claim 7 adds a two-to-16-hour Tmax shift, while claim 8 requires maintained bioavailability.
Osmolex ER is the commercial product most directly aligned with the osmotic and once-daily claim structure.
Gocovri is a competing extended-release amantadine product but requires a separate formulation, PK, ownership, and patent analysis.
The patent issued in 2014 and has an estimated ordinary term extending to approximately 2031, subject to the official USPTO patent-term calculation and any applicable adjustments.
Generic risk is concentrated in extended-release products that fall within the 50 mg to 500 mg dose range and reproduce the claimed human PK profile.
Amantadine has no biosimilar pathway. Competitive entry proceeds through generic-drug and formulation-specific strategies.

FAQs

Can a generic avoid US 8,889,740 by using a non-osmotic extended-release formulation?

Not necessarily. A non-osmotic product may avoid claim 2, but it can still infringe claim 1 if it contains the required amount of amantadine, has at least 50% extended-release drug, and meets the dC/dT limitation.

Does a 100 mg amantadine product fall within the patent?

Yes. A 100 mg product is within claim 1 and also falls within claim 3, assuming the other release and pharmacokinetic limitations are satisfied.

Does an immediate-release loading dose avoid the patent?

No. Claim 9 expressly covers a dosage form that includes immediate-release amantadine. The product must still satisfy the extended-release percentage and PK requirements.

Does FDA approval prove infringement of US 8,889,740?

No. FDA approval and patent infringement are separate legal issues. Approval may indicate that the product met regulatory standards, but it does not establish that every patent claim is infringed.

Can a generic launch before the estimated 2031 patent expiry?

Potentially, but only through a legally effective route such as a successful Paragraph IV challenge, a settlement or license, a noninfringing product design, a valid patent-term determination permitting entry, or a final court ruling removing the patent barrier.

References

United States Patent and Trademark Office. (2014). US Patent No. 8,889,740, once-daily amantadine dosage forms. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
U.S. Food and Drug Administration. (2018). Osmolex ER prescribing information. NDA 209530.
U.S. Food and Drug Administration. (2017). Gocovri prescribing information. NDA 208944.
Federal Trade Commission. (2024). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act. https://www.ftc.gov
Supernus Pharmaceuticals, Inc. (2021). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2588296	⤷ Start Trial
European Patent Office	1845968	⤷ Start Trial
European Patent Office	2623099	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2006058236	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,889,740